Heparin

Prophylactic dose heparin use during pregnancy in women with Fontan physiology was not significantly associated with increased bleeding risk compared to no antithrombotic therapy (OR 4.68, 95% CI 0.48

Effect: null; OR 4.68; CI: 95% CI 0.488 to 44.9

Prophylactic dose heparin use during pregnancy in women with Fontan physiology was not significantly associated with increased bleeding risk compared to no antithrombotic therapy (OR 4.68, 95% CI 0.48

Effect: null; OR 4.68; CI: 95% CI 0.488 to 44.9

Prophylactic dose heparin use during pregnancy in women with Fontan physiology was not significantly associated with increased bleeding risk compared to no antithrombotic therapy (OR 4.68, 95% CI 0.48

Effect: null; OR 4.68; CI: 95% CI 0.488 to 44.9

Prophylactic dose heparin use during pregnancy in women with Fontan physiology was not significantly associated with increased bleeding risk compared to no antithrombotic therapy (OR 4.68, 95% CI 0.48

Effect: null; OR 4.68; CI: 95% CI 0.488 to 44.9

Prophylactic dose heparin use during pregnancy in women with Fontan physiology was not significantly associated with increased bleeding risk compared to no antithrombotic therapy (OR 4.68, 95% CI 0.48

Effect: null; OR 4.68; CI: 95% CI 0.488 to 44.9

Prophylactic dose heparin use during pregnancy in women with Fontan physiology was not significantly associated with increased bleeding risk compared to no antithrombotic therapy (OR 4.68, 95% CI 0.48

Effect: null; OR 4.68; CI: 95% CI 0.488 to 44.9

Prophylactic dose heparin use during pregnancy in women with Fontan physiology was not significantly associated with increased bleeding risk compared to no antithrombotic therapy (OR 4.68, 95% CI 0.48

Effect: null; OR 4.68; CI: 95% CI 0.488 to 44.9

Prophylactic dose heparin use during pregnancy in women with Fontan physiology was not significantly associated with increased bleeding risk compared to no antithrombotic therapy (OR 4.68, 95% CI 0.48

Effect: null; OR 4.68; CI: 95% CI 0.488 to 44.9

Prophylactic dose heparin use during pregnancy in women with Fontan physiology was not significantly associated with increased bleeding risk compared to no antithrombotic therapy (OR 4.68, 95% CI 0.48

Effect: null; OR 4.68; CI: 95% CI 0.488 to 44.9

Prophylactic dose heparin use during pregnancy in women with Fontan physiology was not significantly associated with increased bleeding risk compared to no antithrombotic therapy (OR 4.68, 95% CI 0.48

Effect: null; OR 4.68; CI: 95% CI 0.488 to 44.9

Prophylactic dose heparin use during pregnancy in women with Fontan physiology was not significantly associated with increased bleeding risk compared to no antithrombotic therapy (OR 4.68, 95% CI 0.48

Effect: null; OR 4.68; CI: 95% CI 0.488 to 44.9

Prophylactic dose heparin use during pregnancy in women with Fontan physiology was not significantly associated with increased bleeding risk compared to no antithrombotic therapy (OR 4.68, 95% CI 0.48

Effect: null; OR 4.68; CI: 95% CI 0.488 to 44.9

Prophylactic dose heparin use during pregnancy in women with Fontan physiology was not significantly associated with increased bleeding risk compared to no antithrombotic therapy (OR 4.68, 95% CI 0.48

Effect: null; OR 4.68; CI: 95% CI 0.488 to 44.9

Prophylactic dose heparin use during pregnancy in women with Fontan physiology was not significantly associated with increased bleeding risk compared to no antithrombotic therapy (OR 4.68, 95% CI 0.48

Effect: null; OR 4.68; CI: 95% CI 0.488 to 44.9

Prophylactic dose heparin use during pregnancy in women with Fontan physiology was not significantly associated with increased bleeding risk compared to no antithrombotic therapy (OR 4.68, 95% CI 0.48

Effect: null; OR 4.68; CI: 95% CI 0.488 to 44.9

Prophylactic dose heparin use during pregnancy in women with Fontan physiology was not significantly associated with increased bleeding risk compared to no antithrombotic therapy (OR 4.68, 95% CI 0.48

Effect: null; OR 4.68; CI: 95% CI 0.488 to 44.9

Prophylactic dose heparin use during pregnancy in women with Fontan physiology was not significantly associated with increased bleeding risk compared to no antithrombotic therapy (OR 4.68, 95% CI 0.48

Effect: null; OR 4.68; CI: 95% CI 0.488 to 44.9

Prophylactic dose heparin use during pregnancy in women with Fontan physiology was not significantly associated with increased bleeding risk compared to no antithrombotic therapy (OR 4.68, 95% CI 0.48

Effect: null; OR 4.68; CI: 95% CI 0.488 to 44.9

Prophylactic dose heparin use during pregnancy in women with Fontan physiology was not significantly associated with increased bleeding risk compared to no antithrombotic therapy (OR 4.68, 95% CI 0.48

Effect: null; OR 4.68; CI: 95% CI 0.488 to 44.9

Prophylactic dose heparin use during pregnancy in women with Fontan physiology was not significantly associated with increased bleeding risk compared to no antithrombotic therapy (OR 4.68, 95% CI 0.48

Effect: null; OR 4.68; CI: 95% CI 0.488 to 44.9

Prophylactic dose heparin use during pregnancy in women with Fontan physiology was not significantly associated with increased bleeding risk compared to no antithrombotic therapy (OR 4.68, 95% CI 0.48

Effect: null; OR 4.68; CI: 95% CI 0.488 to 44.9

Prophylactic dose heparin use during pregnancy in women with Fontan physiology was not significantly associated with increased bleeding risk compared to no antithrombotic therapy (OR 4.68, 95% CI 0.48

Effect: null; OR 4.68; CI: 95% CI 0.488 to 44.9

Prophylactic dose heparin use during pregnancy in women with Fontan physiology was not significantly associated with increased bleeding risk compared to no antithrombotic therapy (OR 4.68, 95% CI 0.48

Effect: null; OR 4.68; CI: 95% CI 0.488 to 44.9

Prophylactic dose heparin use during pregnancy in women with Fontan physiology was not significantly associated with increased bleeding risk compared to no antithrombotic therapy (OR 4.68, 95% CI 0.48

Effect: null; OR 4.68; CI: 95% CI 0.488 to 44.9

Prophylactic dose heparin use during pregnancy in women with Fontan physiology was not significantly associated with increased bleeding risk compared to no antithrombotic therapy (OR 4.68, 95% CI 0.48

Effect: null; OR 4.68; CI: 95% CI 0.488 to 44.9

Prophylactic dose heparin use during pregnancy in women with Fontan physiology was not significantly associated with increased bleeding risk compared to no antithrombotic therapy (OR 4.68, 95% CI 0.48

Effect: null; OR 4.68; CI: 95% CI 0.488 to 44.9

Prophylactic dose heparin use during pregnancy in women with Fontan physiology was not significantly associated with increased bleeding risk compared to no antithrombotic therapy (OR 4.68, 95% CI 0.48

Effect: null; OR 4.68; CI: 95% CI 0.488 to 44.9